Working... Menu
Trial record 52 of 59 for:    MLN8237

A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02700022
Recruitment Status : Terminated (Lack of funding)
First Posted : March 7, 2016
Last Update Posted : November 20, 2017
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
UNC Lineberger Comprehensive Cancer Center

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : November 15, 2016
  Actual Study Completion Date : August 18, 2017